Minister, I'd like to come back to a question that my colleague, Dr. Morin, raised.
Although one could say that there's a measure of responsibility for the pharmaceutical companies that are producing these drugs, and that's very important, at the end of the day, as I see the legislation, it's actually Health Canada, your department, that has to do the heavy lifting in terms of seeing this process through. For example, it gives you the power to call for more studies. It gives you the power to actually make a recall, to require labelling, to do follow-up.
You're not going to do that on your own. You have to have experts who are helping you do that. I do want to say that nothing would be worse than passing this law only to find that we actually don't have the resources within the department to undertake the levels of work and the further research that might be required to actually put this law into effect.
There have been cuts at Health Canada, so I think it would be very helpful for the committee to know, for example, what additional resources your department will be able to draw on in order to actually implement and enforce this bill, assuming that it is passed by the House.